Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18667774 | 0.89 | TP53 (0.48) | EGLN1POLBKMT2ATDP1 | |
| SCHEMBL19984758 | 0.88 | EGLN1 (0.41) | EGLN1POLBKMT2ATDP1ROCK2 | |
| SCHEMBL21291405 | 0.87 | EGLN1 (0.42) | EGLN1KLKB1ROCK2ROCK1 | |
| SCHEMBL21291407 | 0.86 | EGLN1 (0.42) | EGLN1KLKB1ROCK2ROCK1 | |
| SCHEMBL18667815 | 0.81 | EGLN1 (0.45) | EGLN1KLKB1ROCK2 | |
| SCHEMBL21291308 | 0.81 | EGLN1 (0.40) | EGLN1KLKB1ROCK2 | |
| SCHEMBL18667414 | 0.81 | EGLN1 (0.44) | EGLN1POLBKMT2A | |
| SCHEMBL18667797 | 0.80 | TP53 (0.47) | EGLN1POLBKMT2ATDP1 | |
| SCHEMBL18667573 | 0.79 | EGLN1 (0.40) | EGLN1POLBKMT2ATDP1ROCK2 | |
| SCHEMBL19984690 | 0.79 | IP6K1 (0.41) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | EGLN1 3738/4885POLB 1770/4885KMT2A 3876/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | EGLN1 3738/4885POLB 1770/4885KMT2A 3876/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | EGLN1 3738/4885POLB 1770/4885KMT2A 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.